Revvity announces SuperFlex prenatal screening system for accessible, rapid preeclampsia testing
The new SuperFlex platform provides flexible throughput, quick results in 14 minutes, and supports both first- and second-trimester screening, making it ideal for decentralized and low-volume workflows worldwide.
Revvity, Inc. announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.
The system supports testing for preeclampsia and offers:
Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low
Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle software for streamlined risk assessment and LIMS data transfer
Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows
A test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing.
The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
